Amniotic tissue allografts have moved from a niche research interest to a product line that veterinarians can order and keep on hand. For a general practitioner or a surgical specialist evaluating whether to add one to a case plan, the useful questions are not abstract. What is actually in the material? How is it made and kept stable until use? What does a reasonable evaluation process look like before recommending it to a client? This post walks through each of those, along with what veterinarians using AlphaFlo® have reported in their own case work.
What Is an Amniotic Tissue Allograft?
The amniotic membrane is the innermost layer of the placental tissue that surrounds a developing fetus. It is a source of extracellular matrix proteins, hyaluronic acid, amino acids, and a range of cytokines and growth factors, which is why tissue banks have used it in human wound care and orthopedic applications before it reached veterinary medicine.
AlphaFlo® is a liquid, acellular amniotic tissue allograft made specifically for dogs. AlphaLogix sources the canine tissue during live births, using licensed veterinarians and sterile recovery techniques so the process does not harm the mother or puppies. Because the allograft is acellular, it does not carry live donor cells into the recipient; what it carries is the matrix and the signaling proteins the tissue naturally contains.
Independent literature on amniotic tissue generally reports anti-inflammatory, immunomodulatory, antifibrotic, and regenerative properties.1 Several specific factors have been identified in AlphaFlo® by name:
| Factor | General category |
|---|---|
| A2M | Anti-inflammatory properties |
| IL-1ra | Anti-inflammatory properties |
| IL-10 | Anti-inflammatory properties |
| TIMP-2 | Antifibrotic properties |
| MCP-1 | Immune signaling properties |
| IL-15 | Immune signaling properties |
| Trappin-2 | Antimicrobial properties |
| EGFR | Growth factor pathway properties |
| VEGF | Angiogenic properties |
These are reported properties of amniotic tissue as a category, cited to the literature below, not a guarantee of outcome for any individual patient. As with any allograft, use may not improve a dog’s condition, and there is a possibility of an adverse reaction.
How Is AlphaFlo® Prepared?
Preparation starts at recovery. Tissue is collected under sterile conditions at the time of a live birth, then moves into manufacturing. The manufacturing process is designed to preserve the native tissue and retain its naturally occurring proteins, which is the reason AlphaFlo® is supplied as a liquid, frozen allograft rather than a freeze dried one. Freeze drying is a common method in this category, but it can affect some of the proteins the tissue is valued for in the first place.
AlphaLogix follows current Good Tissue Practices modeled on human tissue standards. Each lot is aseptically manufactured and tested against USP standards, including sterility, before release.
How Is AlphaFlo® Stored Before Use?
AlphaFlo® is supplied frozen and kept frozen at the practice until it is needed. It comes in three volumes, 0.5cc, 1.0cc, and 2.0cc, so the amount on hand can match the size of the case rather than forcing a single dose format on every patient.
Because it is a ready to use allograft, there is no cell culturing step and no patient side harvest procedure before it can be administered. That is the main practical difference from autologous options like platelet rich plasma, where the material has to be drawn from the patient and processed in house before each use, and where the resulting protein concentration can vary from one blood draw to the next. An allograft that is manufactured and tested in advance is intended to reduce that variability.
How Do Veterinarians Evaluate a Case for an Amniotic Allograft?
There is no single checklist here, and any decision to use an amniotic allograft is at the treating veterinarian’s discretion. In practice, that evaluation tends to weigh a few things together: the specific tissue involved, what else has already been tried, how the patient has responded to prior care, and an honest conversation with the owner about how the allograft can and cannot be expected to help.
Published case studies from veterinarians using AlphaFlo® span a wide range of presentations. These are individual case studies, not controlled clinical trials, and they should be read that way. Their value is in showing how other clinicians have reasoned through similar decisions, not in predicting what will happen in the next case.
What Has Clinical Experience Looked Like in Practice?
Mark Besançon, DVM, who authored AlphaFlo®’s tibial plateau leveling osteotomy case study, described his own shift in practice this way:
“I now start with AlphaFlo® as a foundational product and layer traditional therapies as needed. The shift wasn’t philosophical; it was clinical. As outcomes improved and cases responded more quickly and more completely, it became clear that this tool belongs at the front of the care plan, not in the ‘extras’ column.”
Where This Leaves the Decision
As a prescription product, AlphaFlo® is administered only by a licensed veterinarian. It is not a replacement for surgery, a drug, or a course of treatment already working for a patient. It is one more option to weigh, with a story that is worth understanding before it comes up in an exam room conversation. Veterinarians who want more detail on the sourcing, testing, and case data behind AlphaFlo® are welcome to request more information or join a Lunch & Learn session hosted by Christian Beaudry, Chief Operating and Scientific Officer.
References
1. Avilla-Royo, E., et al. (2021). Amniotic membrane derived products in regenerative medicine: reported properties and applications.
2. Barrientos, S., et al. (2008). Growth factors and cytokines in wound healing.